90 related articles for article (PubMed ID: 16236616)
1. Nitrogen-containing bisphosphonate incadronate augments the inhibitory effect of farnesyl transferase inhibitor tipifarnib on the growth of fresh and cloned myeloma cells in vitro.
Ochiai N; Yamada N; Uchida R; Fuchida S; Okano A; Okamoto M; Ashihara E; Inaba T; Shimazaki C
Leuk Lymphoma; 2005 Nov; 46(11):1619-25. PubMed ID: 16236616
[TBL] [Abstract][Full Text] [Related]
2. Effect of farnesyl transferase inhibitor R115777 on the growth of fresh and cloned myeloma cells in vitro.
Ochiai N; Uchida R; Fuchida S; Okano A; Okamoto M; Ashihara E; Inaba T; Fujita N; Matsubara H; Shimazaki C
Blood; 2003 Nov; 102(9):3349-53. PubMed ID: 12842991
[TBL] [Abstract][Full Text] [Related]
3. The bisphosphonate incadronate (YM175) causes apoptosis of human myeloma cells in vitro by inhibiting the mevalonate pathway.
Shipman CM; Croucher PI; Russell RG; Helfrich MH; Rogers MJ
Cancer Res; 1998 Dec; 58(23):5294-7. PubMed ID: 9850051
[TBL] [Abstract][Full Text] [Related]
4. The farnesyl transferase inhibitor, tipifarnib, is a potent inhibitor of the MDR1 gene product, P-glycoprotein, and demonstrates significant cytotoxic synergism against human leukemia cell lines.
Medeiros BC; Landau HJ; Morrow M; Lockerbie RO; Pitts T; Eckhardt SG
Leukemia; 2007 Apr; 21(4):739-46. PubMed ID: 17268526
[TBL] [Abstract][Full Text] [Related]
5. Tipifarnib-induced apoptosis in acute myeloid leukemia and multiple myeloma cells depends on Ca2+ influx through plasma membrane Ca2+ channels.
Yanamandra N; Buzzeo RW; Gabriel M; Hazlehurst LA; Mari Y; Beaupre DM; Cuevas J
J Pharmacol Exp Ther; 2011 Jun; 337(3):636-43. PubMed ID: 21378206
[TBL] [Abstract][Full Text] [Related]
6. Farnesyltransferase inhibitor tipifarnib is well tolerated, induces stabilization of disease, and inhibits farnesylation and oncogenic/tumor survival pathways in patients with advanced multiple myeloma.
Alsina M; Fonseca R; Wilson EF; Belle AN; Gerbino E; Price-Troska T; Overton RM; Ahmann G; Bruzek LM; Adjei AA; Kaufmann SH; Wright JJ; Sullivan D; Djulbegovic B; Cantor AB; Greipp PR; Dalton WS; Sebti SM
Blood; 2004 May; 103(9):3271-7. PubMed ID: 14726402
[TBL] [Abstract][Full Text] [Related]
7. Driven to death: Inhibition of farnesylation increases Ras activity and promotes growth arrest and cell death [corrected].
Geryk-Hall M; Yang Y; Hughes DP
Mol Cancer Ther; 2010 May; 9(5):1111-9. PubMed ID: 20406948
[TBL] [Abstract][Full Text] [Related]
8. A newly developed bisphosphonate, YM529, is a potent apoptosis inducer of human myeloma cells.
Takahashi R; Shimazaki C; Inaba T; Okano A; Hatsuse M; Okamoto A; Hirai H; Ashihara E; Nakagawa M
Leuk Res; 2001 Jan; 25(1):77-83. PubMed ID: 11137564
[TBL] [Abstract][Full Text] [Related]
9. Tipifarnib prevents development of hypoxia-induced pulmonary hypertension.
Duluc L; Ahmetaj-Shala B; Mitchell J; Abdul-Salam VB; Mahomed AS; Aldabbous L; Oliver E; Iannone L; Dubois OD; Storck EM; Tate EW; Zhao L; Wilkins MR; Wojciak-Stothard B
Cardiovasc Res; 2017 Mar; 113(3):276-287. PubMed ID: 28395021
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of farnesyl:protein transferase and geranylgeranyl:protein transferase inhibitor combinations in preclinical models.
Lobell RB; Omer CA; Abrams MT; Bhimnathwala HG; Brucker MJ; Buser CA; Davide JP; deSolms SJ; Dinsmore CJ; Ellis-Hutchings MS; Kral AM; Liu D; Lumma WC; Machotka SV; Rands E; Williams TM; Graham SL; Hartman GD; Oliff AI; Heimbrook DC; Kohl NE
Cancer Res; 2001 Dec; 61(24):8758-68. PubMed ID: 11751396
[TBL] [Abstract][Full Text] [Related]
11. Characterization of a R115777-resistant human multiple myeloma cell line with cross-resistance to PS-341.
Buzzeo R; Enkemann S; Nimmanapalli R; Alsina M; Lichtenheld MG; Dalton WS; Beaupre DM
Clin Cancer Res; 2005 Aug; 11(16):6057-64. PubMed ID: 16115951
[TBL] [Abstract][Full Text] [Related]
12. Farnesyl transferase inhibitor R115777 induces apoptosis of human myeloma cells.
Le Gouill S; Pellat-Deceunynck C; Harousseau JL; Rapp MJ; Robillard N; Bataille R; Amiot M
Leukemia; 2002 Sep; 16(9):1664-7. PubMed ID: 12200678
[TBL] [Abstract][Full Text] [Related]
13. Farnesyltransferase inhibitor tipifarnib inhibits Rheb prenylation and stabilizes Bax in acute myelogenous leukemia cells.
Ding H; McDonald JS; Yun S; Schneider PA; Peterson KL; Flatten KS; Loegering DA; Oberg AL; Riska SM; Huang S; Sinicrope FA; Adjei AA; Karp JE; Meng XW; Kaufmann SH
Haematologica; 2014 Jan; 99(1):60-9. PubMed ID: 23996484
[TBL] [Abstract][Full Text] [Related]
14. Tipifarnib and bortezomib are synergistic and overcome cell adhesion-mediated drug resistance in multiple myeloma and acute myeloid leukemia.
Yanamandra N; Colaco NM; Parquet NA; Buzzeo RW; Boulware D; Wright G; Perez LE; Dalton WS; Beaupre DM
Clin Cancer Res; 2006 Jan; 12(2):591-9. PubMed ID: 16428505
[TBL] [Abstract][Full Text] [Related]
15. The farnesyl transferase inhibitor R115777 (Zarnestra) synergistically enhances growth inhibition and apoptosis induced on epidermoid cancer cells by Zoledronic acid (Zometa) and Pamidronate.
Caraglia M; D'Alessandro AM; Marra M; Giuberti G; Vitale G; Viscomi C; Colao A; Prete SD; Tagliaferri P; Tassone P; Budillon A; Venuta S; Abbruzzese A
Oncogene; 2004 Sep; 23(41):6900-13. PubMed ID: 15286715
[TBL] [Abstract][Full Text] [Related]
16. Effect of incadronate on proliferation of mesenchymal tumor cells with or without activated Ras mutation.
Kawashima H; Ogose A; Hotta T; Ito T; Endo N; Kawashima H; Tamura K; Nakano K
J Exp Clin Cancer Res; 2005 Dec; 24(4):617-24. PubMed ID: 16471325
[TBL] [Abstract][Full Text] [Related]
17. Farnesyltransferase inhibition in hematologic malignancies: the clinical experience with tipifarnib.
Martinelli G; Iacobucci I; Paolini S; Ottaviani E
Clin Adv Hematol Oncol; 2008 Apr; 6(4):303-10. PubMed ID: 18496498
[TBL] [Abstract][Full Text] [Related]
18. Anti-inflammatory activity in vitro and in vivo of the protein farnesyltransferase inhibitor tipifarnib.
Xue X; Lai KT; Huang JF; Gu Y; Karlsson L; Fourie A
J Pharmacol Exp Ther; 2006 Apr; 317(1):53-60. PubMed ID: 16352705
[TBL] [Abstract][Full Text] [Related]
19. In vitro profiling of the sensitivity of pediatric leukemia cells to tipifarnib: identification of T-cell ALL and FAB M5 AML as the most sensitive subsets.
Goemans BF; Zwaan CM; Harlow A; Loonen AH; Gibson BE; Hählen K; Reinhardt D; Creutzig U; Heinrich MC; Kaspers GJ
Blood; 2005 Nov; 106(10):3532-7. PubMed ID: 16051737
[TBL] [Abstract][Full Text] [Related]
20. Farnesyltransferase inhibitor tipifarnib (R115777) preferentially inhibits in vitro autonomous erythropoiesis of polycythemia vera patient cells.
Larghero J; Gervais N; Cassinat B; Rain JD; Schlageter MH; Padua RA; Chomienne C; Rousselot P
Blood; 2005 May; 105(9):3743-5. PubMed ID: 15632209
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
